TY - JOUR
T1 - Biologics and Novel Therapeutics in Food Allergy
AU - Anderson, Brent
AU - Pascal, Claire
AU - Butler, M Gohazrua K
AU - Chin, Andrew R
AU - Long, Andrew J
AU - Sindher, Sayantani B
AU - Anagnostou, Aikaterini
AU - Arasi, Stefania
AU - Bégin, Philippe
AU - Ciaccio, Christina E
AU - Eiwegger, Thomas
AU - Fiocchi, Alessandro
AU - Fleischer, David M
AU - Garcia-Llorett, Maria
AU - Kim, Edwin H
AU - Leonard, Stephanie
AU - Maskatia, Zahida Rani
AU - Perrett, Kirsten P
AU - Shreffler, Wayne
AU - Upton, Julia
AU - Chinthrajah, R Sharon
N1 - Publisher Copyright:
© 2026 American Academy of Allergy, Asthma & Immunology
PY - 2026/4
Y1 - 2026/4
N2 - The US Food and Drug Administration approval of omalizumab for the treatment of food allergy has opened the door for therapeutics targeting the underlying mechanisms that drive food allergy. Here we discuss both approved and novel investigational therapeutic strategies targeting these allergic pathways for the treatment of food allergy.
AB - The US Food and Drug Administration approval of omalizumab for the treatment of food allergy has opened the door for therapeutics targeting the underlying mechanisms that drive food allergy. Here we discuss both approved and novel investigational therapeutic strategies targeting these allergic pathways for the treatment of food allergy.
KW - Food Hypersensitivity/immunology
KW - Humans
KW - Biological Products/therapeutic use
KW - Anti-Allergic Agents/therapeutic use
KW - Omalizumab/therapeutic use
KW - United States Food and Drug Administration
KW - United States
KW - Animals
KW - Immunoglobulin E/immunology
KW - Drug Approval
UR - https://www.scopus.com/pages/publications/105034892138
U2 - 10.1016/j.jaip.2026.01.044
DO - 10.1016/j.jaip.2026.01.044
M3 - Review article
C2 - 41956612
SN - 2213-2198
VL - 14
SP - 762
EP - 770
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 4
ER -